Eyeseryl vs Matrixyl Synthe'6
Head-to-head comparison of Eyeseryl (Acetyl Tetrapeptide-5) and Matrixyl Synthe'6 (Palmitoyl Tripeptide-38) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Eyeseryl | Matrixyl Synthe'6 |
|---|---|---|
| Category | Skin & Cosmetic | Skin & Cosmetic |
| Full Name | Acetyl Tetrapeptide-5 | Palmitoyl Tripeptide-38 |
| Molecular Weight | 492.5 Da | 675.9 Da |
| Half-Life | N/A | N/A |
| Amino Acids | 4 | 3 |
| Typical Dose | 0.5-2% in eye-area cosmetic products | 0.1-2% in finished skincare products |
| Route | Topical | Topical |
| Purity | ≥98% | ≥98% |
| Studies Count | 18 | 16 |
| Research Status | Clinical | Pre-clinical |
Eyeseryl Benefits
- ✓under-eye puffiness reduction
- ✓cosmetic firming support
- ✓appearance of dark circles
- ✓eye-area smoothing
Matrixyl Synthe'6 Benefits
- ✓collagen-supportive skincare
- ✓fine-line appearance reduction
- ✓skin-firming support
- ✓matrix-support formula ingredient
Eyeseryl Dosing
Topical eye cream 0.5-2%|Apply 1-2x daily under eyes|Use gently on intact skin only
Matrixyl Synthe'6 Dosing
Topical serum/cream 0.1-2%|Apply 1-2x daily|Best used in long-term routines
Eyeseryl Side Effects
- ⚠eye-area irritation
- ⚠dryness
- ⚠rare contact allergy
Matrixyl Synthe'6 Side Effects
- ⚠mild irritation
- ⚠clogging in heavy formulas
- ⚠rare sensitivity to fatty vehicles
Research Overview
Eyeseryl
Acetyl tetrapeptide-5 has topical cosmetic literature and formulation studies focused on edema reduction and eye-contour improvement. It is mainly used for appearance benefits rather than as a systemic therapeutic peptide.
Matrixyl Synthe'6
Palmitoyl tripeptide-38 has a mix of published cosmetic research and formulation data suggesting benefits for skin appearance and matrix-support signaling. Its practical use is as a topical anti-aging ingredient in combination with hydrators and barrier-support agents.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.